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a b s t r a c t
Spexin mRNA and protein are widely expressed in rat tissues and associate with weight loss in rodents
of diet-induced obesity. Its location in endocrine and epithelial cells has also been suggested. Spexin
is a novel peptide that involves weight loss in rodents of diet-induced obesity. Therefore, we aimed to
examine its expression in human tissues and test whether spexin could have a role in glucose and lipid
metabolism in type 2 diabetesmellitus (T2DM). The expression of the spexin gene and immunoreactivity
in the adrenal gland, skin, stomach, small intestine, liver, thyroid, pancreatic islets, visceral fat, lung,
colon, and kidney was higher than that in the muscle and connective tissue. Immunoreactive serum
spexin levels were reduced in T2DM patients and correlated with fasting blood glucose (FBG, r=−0.686,
P<0.001), hemoglobin A1c (HbA1c, r=−0.632, P<0.001), triglyceride (TG, r=−0.236, P<0.001) and low
density lipoprotein-cholesterol (LDL-C, r=−0.382, P<0.001). A negative correlation of blood glucosewith
spexin was observed during oral glucose tolerance test (OGTT). Spexin is intensely expressed in normal
human endocrine and epithelial tissues, indicating that spexinmay be involved in physiological functions
of endocrineand in several other tissues. Circulating spexin levels are low inT2DMpatients andnegatively
related to blood glucose and lipids suggesting that the peptide may play a role in glucose and lipid
metabolism in T2DM.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Spexin is a peptide that was identiﬁed through modern bioin-
formatics search strategies [1,2]. In humans, spexin is a product of
the Ch12orf39 gene. The prepropeptide is composed of 116 amino
acid residues (GeneBank database XM 001076968) Mature spexin
contains 14 amino acids. Rat spexin differs from the human and
mouse peptide sequences by one amino acid within the C-terminal
portion, ending with the sequence GHR instead of GRR [2].
Previous studies have revealed the widespread expression of
spexin mRNA and protein in rat tissues including the hypo-
thalamus, cerebral cortex, hippocampus, pons, retina, esophagus,
stomach, kidney, ovary, and adrenal gland [3]. Its location in
endocrine cells and its ability to be secreted suggest its possible
role as an endocrine factor. Moreover, an important role of spexin
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in the functioning of epithelial cells has also been suggested [3].
However, the expression of spexin mRNA and protein in human
tissues is unknown. In this study, we examined its expression in
human tissues, particularly endocrine and epithelial tissues.
Little is known about the functions of spexin. The synthetic
amidated spexin peptide NWTPQAMLYLKGAQ-amide has been
found to induce muscle contraction in a dose-dependent man-
ner in a stomach explant contractility assay [1]. Recent studies
have demonstrated that spexin reduces the rate of adrenocortical
cell proliferation and may evoke an increase in aldosterone and
glucocorticoid secretion in some rat adrenocortical cell cultures
and modulate cardiovascular and renal functions and nociception
[4,5]. Treatment of goldﬁsh with spexin decreased the secretion of
luteinizing hormone and suppressed appetite [6,7]. Despite accu-
mulating evidence for physiological roles of spexin, other functions
of spexin have not yet been demonstrated. Identiﬁcation of the tis-
sue or cell types that express spexin in humans would contribute
to clarifying its physiological function, especially in type 2 diabetes
mellitus (T2DM).
T2DM is associated with disturbances in glucose and lipid
metabolism usually caused by sedentary life style and increased
food consumption. Recent studies have shown a relationship
http://dx.doi.org/10.1016/j.peptides.2015.07.018
0196-9781/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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between spexin and body weight regulation [7,8]. In particu-
lar, spexin gene expression is markedly down-regulated in obese
human fat. The peptide produces weight loss in rodent models of
diet-induced obesity. These ﬁndings suggest that spexin might be
related to glucose homeostasis and lipid metabolism in T2DM. In
this study we wanted to examine spexin localization in human
tissues and circulating spexin levels after glucose load in T2DM
patients.
2. Materials and methods
2.1. Human samples
Three to four samples of normal adult human thyroid, pancreas,
adrenal gland, visceral fat, skin, small intestine, colon, stomach,
liver, lung, kidney, skeletal muscle, myometrium and bladder
smooth muscle were obtained from surgical human specimens in
the Department of Pathology at Shanghai General Hospital afﬁl-
iated to Shanghai Jiao Tong University School. 38 subjects (20
males and 18 females aged 28–72y) were examined. For real-time
PCR studies, the tissues (approximately 0.5 cm3) were immedi-
ately stored in liquid nitrogen. Tissues (approximately 0.5 cm3) for
immunohistochemical stainingwereﬁxed in10%buffered formalin
for 48h and parafﬁn embedded.
Nextwe enrolled 121 subjects with T2DMand 105 healthy indi-
viduals participated in the study as control subjects. None of the
healthy volunteers were taking any medication, and none had a
ﬁrst-degree relative with T2DM. Those with hypertension, acute
or chronic infectious disease, autoimmune diseases, heart failure,
hepatic disease, or renal disease were excluded. Blood samples
were collected at rest at 8:00A.M., after an overnight fast and 24h
alcohol abstention. Serum was separated into vials and stored at
−80 ◦C.
We also enrolled 12 healthy volunteers (aged: 52.8±9.2 years
with BMI: 23.3±1.8 kg/m2) including 5males and 7 females in our
study.Nonewere taking anymedicationaffectingglucose tolerance
(-blockers, thiazide diuretics, and corticoids) and none had a ﬁrst
degree relative with T2DM. Oral glucose tolerance test (OGTT) was
performed using the International Expert Committee criteria [9].
The study was approved by the Institutional Review Board of
Shanghai General Hospital afﬁliated to Shanghai Jiao Tong Uni-
versity School of Medicine (diary code, 2014KY094) and was
performed in accordance with the principle of the Helsinki Dec-
laration.
2.2. Conventional RT-PCR and quantitative real-time PCR
PCRs were performed using the methods as previously
described [3,10–12]. Brieﬂy, total RNA was extracted using TRIzol
Reagent (Invitrogen; Carlsbad, CA, USA); mRNA was extracted
from the total RNA using the PolyATtract mRNA Isolation System
III (Promega; Madison, WI, USA). RT was performed using AMV
Reverse TranscriptasewithOligodT asprimers (Promega;Madison,
WI, USA). The primers used were designed by Primer 5 software
(Whitehead Institute for Biomedical Research; Cambridge, MA,
USA). The primer sequences for Spexin were 5′- GAGGCAGCAAC-
CATCTTA -3′ (forward) and 5′-TTCACCAGTTAAGCAGACT-3′
(reverse). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal control, and its primers were as follows:
5′-ATGGGGAAGGTGAAGGTCG-3′ (forward) and 5′- GGGGT-
CATTGATGGCAACAATA -3′ (reverse). For all of the tested genes, 35
cycles of the following sequenceswere applied: denaturation, 94 ◦C
for 30 s; annealing, 60◦C for 60 s; and extension, 68 ◦C for 60 s. The
reaction products were separated on 2% agarose gels containing
ethidium bromide and photographed with a transilluminator.
Quantitative real-time PCR (qRT-PCR) was performed bymeans
of Applied Biosystems ViiATM 7 (Life Technologies; Burlington,
ON, USA). The SYBR green detection system was used with the
above-mentioned primers, which were also used for conventional
RT-PCR. Each of the 20l reaction mixtures contained 2l of tem-
plate cDNA (or standards or control), 0.8l of each gene-speciﬁc
primer (2.5mol/L), 0.4l ROX Reference Dye II and 10l 2× SYB
Green Premix Ex TaqTM (Takara; Tokyo, Japan). The real-time
PCR program included a 10-min denaturation step to activate the
TaqDNA polymerase, followed by a three-step ampliﬁcation pro-
gram (denaturation at 95 ◦C for 10 s, annealing at 60 ◦C for 5 s, and
extension at 72 ◦C for 10 s). At the end of the reaction process, the
dissociation curve was derived by heating the amplicon from 60
to 95 ◦C. All qRT-PCRs were run in both technical and biological
triplicates. The speciﬁcity of the reaction products was checked
by determining their melting points (0.1 ◦C/sec transition rate).
PCR efﬁciency was calculated by converting the slope produced by
the linear regression of the curves to percentage efﬁciency using
the formula: Efﬁciency=−1+10(−1/slope) as previously described
[13]. The obtained results were normalized to GAPDH, which was
usedas a referencegene.Datawas analyzedusing the2 (−delta deltaCt)
methods as previously described [14]. Relative spexin expression
is calculated relative to the expression of spexin in skeletal muscle.
2.3. Immunohistochemistry
Immunohistochemical analysis was performed as previously
described [15,16]. Sections of human samples were hydrated
gradually through decreasing concentrations of ethanol and then
washed in deionized H2O. They were incubated in 0.3% hydrogen
peroxide for 10min at room temperature to quench endoge-
nous peroxidase activity and then in blocking serum (2% normal
goat serum) for 30min. The sections of human samples were
incubated with primary rabbit polyclonal antibody recognizing
spexin and pro/prepro-peptide (H-023-81; Phoenix Pharmaceut-
icals, Burlingame, CA, USA) diluted 1:200 in PBS for 1h at room
temperature. The sections of human samples were then washed
three times for 5min each in PBS, incubatedwith anti-rabbit serum
for 30min (catalog no. MP-7500; Vector Laboratories, Burlingame,
CA, USA), and then developed in DAB (Sigma–Aldrich; Milan, Italy).
Finally, the sections were counterstained with hematoxylin. Neg-
ative controls were performed by the omission of the primary
antibody. Spexin immunoreactivity detected in human stomach
was used as a positive control, as suggested in the datasheet of
the antibody. To verify the immunohistochemical speciﬁcity of
the reaction, absorption tests with spexin (No.023-81; Phoenix
Pharmaceuticals) were also performed.
Immunohistochemical staining for spexin was evaluated by
scanning entire tissue specimens under low power magniﬁca-
tion (5×) and later conﬁrmed under high power magniﬁcations
(10×, 20×, and 40×). Immunohistochemical evaluation included
the number of positive cells and staining intensity. Overall staining
area and intensity was stratiﬁed as follows: −, negative; ±, barely
detectable; +,weak; + +,moderate; and +++, strong [15]. Image-Pro
plus 6 software was used to quantify the integrated optical density
(IOD).
2.4. Anthropometric, biochemical measurements and spexin
immunoassay
All subjects were assessed after overnight fasting. Body weight,
height, systolic pressure (SBP), and diastolic pressure (DBP) were
measured by an experienced physician. BMI was calculated as
weight in kilograms divided by height in meters squared. Fas-
ting blood glucose (FBG), triglyceride (TG), total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), and high-density
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Table 1
Spexin immunoreactivity in normal human tissues.
Tissues and organs Cell types Cytoplasmic positivity
Thyroid Follicular epithelium +
Parafollicular cells +
Islets of Langerhans cells + + +
Adrenal gland Cortex +++
Medulla + ++
Ganglionic cells + + +
Visceral fat Adipocyte + +
Skin Epidermis + +
Stomach Superﬁcial epithelium ±
Base of glands +++
Small intestine Epithelium +++
Colon Epithelium +++
Liver Hepatocytes + ++
Exocrine pancreas Acinar epithelium ±
Ductal epithelium –
Lung Alveolar epithelium ++
Bronchial epithelium ++
Kidney Renal corpuscles ±
Tubular epithelium +++
Skeletal muscle Muscle cells ±
Connective tissue Fibroblasts –
Smooth muscle (uterus) Muscle cells ±
Smooth muscle (bladder) Muscle cells ±
Immunostaining area and intensity were graded as follows: −: negative; ±: barely
detectable; +: weak; ++: moderate; and +++: strong.
lipoprotein cholesterol (HDL-C) were measured using an auto-
analyser (Beckman, CA, USA). Plasma glucose concentrations were
measured using the oxidase method. Hemoglobin A1c (HbA1c)
was evaluated by a high performance liquid chromatography tech-
nique (HPLC VariantTM, Bio-Rad, Germany). Spexin was analyzed
by an enzyme-linked immunosorbent assay (CSB-EL003071HU,
CUSABIO, Wuhan, China). All measurements were performed in
duplicate, and themean of the twomeasurements was considered.
The linear range of the assay was 0.0625 −4ng/ml.
2.5. Statistical analysis
Statistical analysiswasperformedusing the SPSS statistical soft-
ware for Windows (Version 20.0). Numerical data are presented
as mean± SD. Skewed distributed data were logarithmically trans-
formed before analysis. Comparisons between groupswere carried
out using independent-samples t test or paired-samples t test or
one-way ANOVA. To analyze the categorical data, a chi-square test
was used and descriptive statistics are presented as frequency (%).
Correlation analyses adjusted by age, gender and bodyweightwere
performed using Pearson’s test or Partial’s test. The P values below
0.05 were considered statistically signiﬁcant.
3. Results
3.1. Spexin is intensely expressed by gene and
immunohistochemistry in most endocrine tissues, especially the
adrenal gland
Spexin gene was detected in most of the endocrine tissues
we studied, with an at least 10-fold higher expression in human
adrenal gland than in skeletal muscle (Fig. 1A and B). In the
thyroid, pancreas, and visceral fat, the mRNA level of spexin
was approximately 5–10-fold higher than that in skeletal muscle
(Fig 1A, B). Further immunohistochemical detection of spexin pro-
tein conﬁrmed the high expression of spexin (Table 1). We found
widespread spexin immunostaining in human thyroid, adrenal
gland, pancreatic islets and visceral fat, although its expres-
sion levels differed among cell populations (Fig 1C). Spexin was
located primarily in the cytoplasm (See Supplementary ﬁle S1).
In the thyroid, follicular epithelial cells showed heterogeneous
staining. The epithelial cells showed moderate cytoplasmic stain-
ing in some follicles, and no immunostaining in others. Both
the adrenal cortex cells and medullary cells showed intense
cytoplasmic spexin immunostaining. The cells of the islets of
Langerhans showed high spexin immunoreactivity. Visceral fat
cells showedmoderate spexin immunoreactivity. The IODof spexin
staining in pancreatic islets, thyroid, adrenal gland, and visceral
fat were 231,915±19687, 56,396±7287, 521,669±28925, and
97,717±12126, respectively. They were signiﬁcantly higher than
that in skeletal muscle (21,541±1500).
3.2. Spexin is abundant in the epithelia and glands of the main
human organs and tissues
Spexin gene expressions in the skin, stomach, small intestine,
and liver were at least 10-fold higher than that in skeletal muscle
(Fig 2). Thegeneexpressionsof spexin in the colon, lung, andkidney
were 5–10-fold higher than that in skeletal muscle. Immunohis-
tochemical localization of spexin was observed in the epithelia
and glands of most of the examined organs (particularly in the
skin, stomach, small intestine, colon, lung, and renal tubules) and
was exclusively cytoplasmic (Table 1, Fig 3). Along the alimentary
canal, spexin cytoplasmic immunoreactivity was also identiﬁed
in the ganglionic cells of the submucosal and muscle plexuses.
The connective tissue structures (lamina propria and submucosal
layer) showed negative staining while the muscle layers showed
weak/moderate staining. Most of the glandular epithelial cells
in the stomach showed intense cytoplasmic immunostaining.
The immunoreactivity at the base of the gastric glands was more
abundant. The epithelial cells in the small intestine showed high
cytoplasmic immunostaining, whereas the crypt cells showed less
intense. The epithelial cells in the colon showed moderate/strong
cytoplasmic staining, whereas the mucus droplets of goblet cells
showed negative staining. Hepatocytes showed intense cytoplas-
mic staining without nuclear immunoreactivity. The bronchiolar
epithelial cells and alveolar epithelium cells exhibited moderate
cytoplasmic staining. No staining was observed in the tracheal or
bronchial cartilage. The renal corpuscleswere negative for staining.
Positive cytoplasmic immunoreactivity was observed only in the
epithelium of the loop of Henle and the distal tubules. Regarding
the exocrine pancreas, the great majority of acinar secretory cells
were negative, although rare acinar secretory cells withweak cyto-
plasmic immunoreactivity were found. The IOD of spexin staining
in the lung, kidney, skin, small intestine, liver, colon, and stom-
ach were 84,670±11318, 342,897±33830, 187,708±30382,
174,502±17196, 614,126±17871, 159,947±17447, and
229,091±17196, respectively. They were signiﬁcantly higher
than that in the skeletal muscle (21,541±1500).
3.3. Spexin expression is very weak in human muscle and
connective tissues
As shown in Fig. 4A and B, spexin gene expression was very
low in the skeletal muscle, connective tissue, and smooth muscle
(uterus andbladder). Accordingly, skeletalmuscle cells and smooth
muscle cells (uterus and bladder) showed weak immunostaining,
and connective tissue was negative for spexin immunoreactivity
(Fig 4C).
3.4. Serum spexin Levels are lower in T2DM and signiﬁcantly
correlated with glucose and lipid levels
Clinical and biochemical characteristics of the study subjects
were shown in Table 2. Serum levels of spexin were signiﬁ-
cantly lower in T2DM (2.04±0.70ng/mL versus 3.65±0.73ng/mL,
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Fig. 1. Spexin is expressed inmost human endocrine tissues. (A) Conventional RT-PCR analysis of spexin and GAPDH expression in human endocrine tissues. (B) Quantitative
PCR results of relative mRNA expression level in human endocrine tissues. The results were normalized using GAPDH as a reference gene. Relative spexin expression is
calculated relative to the expression of spexin in skeletal muscle. (C) Immunohistochemical staining with spexin antiserum. Bars: Pancreatic islets, Thyroid, Adrenal gland
(Cortex), Adrenal gland (Medulla) = 25m; Adrenal gland, Visceral fat = 100m.
Table 2
Clinical characteristics of the study subjects and correlations with serum spexin in all participants.
Characteristics T2DM Healthy volunteers P value Correlation with serum spexin
r P value
Numbers 121 105
Age (years) 53.4±8.5 51.1±9.1 0.053 −0.084 0.210
Male, n (%) 60(49.6) 58(55.2) 0.425 0.058 0.384
BMI (kg/m2) 22.9±1.4 22.6±1.5 0.178 −0.013 0.841
SBP (mmHg) 125.1±10.6 123.0±9.1 0.108 −0.079 0.241
DBP (mmHg) 75.5±7.1 74.0±6.7 0.092 −0.019 0.781
FBG (mmol/L) 8.1±0.7 5.5±0.3 0.000 −0.686 0.000
HbA1c (%) 7.5±0.6 5.7±0.4 0.000 −0.632 0.000
TG (mmol/L) 1.92±0.49 1.58±0.60 0.000 −0.236 0.000
TC (mmol/L) 4.91±0.54 4.74±0.52 0.017 −0.023 0.729
LDL-C (mmol/L) 3.62±0.50 3.08±0.45 0.000 −0.382 0.000
HDL-C (mmol/L) 0.93±0.28 0.98±0.26 0.182 0.129 0.055
Data are presented as number (percentage) for categorical data and mean± SD for continuous data.
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Fig. 2. Spexin mRNA is expressed in human epithelial and other tissues. (A) Conventional RT-PCR analysis of spexin expression in human epithelial and other tissues. (B)
Quantitative PCR analysis of spexin expression in human epithelial and other tissues. The results were normalized using GAPDH as a reference gene.
P=0.000). Furthermore, correlations between serum spexin levels
and FBG (r=−0.686, P<0.001), HbA1c (r=−0.632, P<0.001) was
observed. And correlations between serum spexin levels and TG
(r=−0.236, P<0.001), LDL-C (r=0.382, P<0.001) also remained sig-
niﬁcant. Spexin levels are associated with those of glucose and
lipids.
3.5. A negative correlation of blood glucose with spexin was
observed during the OGTT
During the OGTT, spexin exhibited a progressive and signiﬁcant
decrease from time 0 to 60min (P<0.05) and returned gradually to
the basal values at 180min. A negative correlation of blood glucose
values with spexin values was observed during the OGTT (Table 3).
4. Discussion
Porzionato et al. [3,17] studied spexin expression in normal rat
tissues and found that spexin was highly expressed in endocrine
cells and epithelial cells in normal rat tissues. As such, we stud-
ied spexin expression in endocrine cells and epithelial cells in
human normal tissues. To our knowledge, the present study is
the ﬁrst in the literature that evaluates spexin expression in the
epithelial,muscle, endocrine, andnumerousotherorgans innormal
humans. Spexin gene expression and immunohistochemical local-
ization detecting spexin and pro/prepro-peptide were consistent
in thyroid, adrenal gland, visceral fat, skin, small intestine, colon,
stomach, liver, lung, skeletal muscle, smooth muscle and connec-
tive tissue. But some small discrepancieswere found in terms of the
levels of expression in pancreas and kidney. This may be primar-
ily due to post-transcriptional regulatory mechanisms of protein
synthesis.
In general, the spexin immunoreactivity in the epithelial cells
of the entire digestive system, respiratory conducting airways,
kidney, and skin were very intense. The highest level of spexin
expression in both simple and stratiﬁed epithelia suggests its
involvement in transepithelial transport (including secretion) and
may also be connected with the regulation of the rate of epithelial
cell renewal. All epithelia are characterized by a high proliferation
rate, and we cannot exclude the role of spexin in themodulation of
proliferation, differentiation, and death of cells in both surface and
glandular epithelia [3]. In particular, spexin immunostaining was
negative or weak in connective tissue, skeletal muscle and smooth
muscle.
Our study revealed spexin expression in all of the endocrine
glands studied and highest levels of expression in adrenal gland,
which is in accordance with the previous ﬁndings that the high-
est levels of spexin mRNA was present in adult rat adrenal glands.
Rucinski et al. [4] found that prolonged ACTH administration
decreasedanddexamethasone increasedadrenal spexinmRNA lev-
els in vivo. The results also suggest the direct involvement of spexin
in the regulation of adrenocortical cell proliferation. Wong et al.
[7] found that spexin mRNA levels in the telencephalon, optic tec-
tum, and hypothalamus of goldﬁsh brain could be elevated by food
intake. Additionally, the injection of spexin into the goldﬁsh brain
inhibited both basal and orexin-induced feeding behavior and food
consumption. Furthermore, the researchers also found that spexin
gene expression was markedly down-regulated in obese human
fat tissue. Spexin is a potent, natural satiety-inducing peptide that
plays a key role in regulating feedingbehavior, uptake of long-chain
fatty acids into adipocytes, energy utilization and metabolism, and
body weight. In diet-induced obesity rats, spexin (35g/kg/day
by intraperitoneal injection daily for 19 days) reduced caloric
intake ∼32% with corresponding weight loss (y=−0.0666×+38.3,
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Fig. 3. Immunohistochemical analysis of the expression of Spexin in human epithelial and other tissues. Bars: Lung, Kidney, Skin, Liver (20×), Colon=25m; Pancreas, Small
intestine, Liver (10×), Stomach=100m.
Table 3
Correlation between serum spexin and glucose during the OGTT.
Time (min) 0 30 60 90 120 180
Glucose(mmol/L) 4.92±0.28 8.28±0.48 7.88±0.29 7.25±0.45 6.05±0.34 4.63±0.35
Spexin (ng/ml) 3.59±0.61 2.47±0.46 2.79±0.48 3.07±0.48 3.23±0.49 3.45±0.58
P value (spexin comparingwith 0min) – 0.001 0.009 0.076 0.107 0.558
Correlation between
spexin and glucose
r −0.644 −0.612 −0.633 −0.744 −0.617 −0.664
P value 0.024 0.034 0.027 0.006 0.033 0.018
Data are presented as mean± SD.
r=−0.7318). Spexin is a novel hormone involved in weight regu-
lation, with the potential for being targeted in obesity therapy [8].
Of special interest is the distribution of spexin immunoreactivity
in the islets of the pancreas of normal human beings. We found
that spexin is highly expressed in the islets of the pancreas of nor-
mal human beings, which is quite different from its expression in
the pancreatic islets of rats [3]. Syntenic analysis and relocating
spexin and their neighbor geneson reconstructedvertebrate ances-
tral chromosomes reveal that spexin resides in the near vicinity
of the kisspeptin and galanin gene families on the chromosomes
[18]. Furthermore, a ligand-receptor interaction study shows that
spexin activate human, Xenopus, and zebra ﬁsh GALR2/3 family
receptors, suggesting that spexin is natural ligand for galanin 2/3.
A positive correlation of galanin with T2DM and metabolic syn-
drome has been previously reported [19–22]. Endogenous galanin
reduces insulin resistance by increasing GLUT4 content and pro-
moting GLUT4 transportation from the intracellular membranes
to the plasma membranes in adipocytes [23]. These results sug-
gest that spexinmay have some relationshipwith T2DM. Therefore
we examined the correlations between serum spexin and blood
glucose and lipid in patients with T2DM. Our data showed that
serum spexin levels were signiﬁcantly lower in T2DM as com-
pared with the lean controls. Meanwhile, a negative correlation of
blood glucose with spexin was observed during the time scale of
OGTT. Signiﬁcant correlations between spexin and blood glucose
and lipids suggest that the peptide may play an important role in
glucose and lipid metabolism in T2DM.
In summary, this study conﬁrms the wide expression of spexin
in normal human tissues. Our data also demonstrates that spexin
is highly expressed among endocrine and epithelial tissues, which
suggests the tissue-speciﬁc functional involvement. Circulating
spexin appears to be inversely related to blood glucose and lipids
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Fig. 4. Spexin expression isweak inhumanmuscle and connective tissues. (A) Conventional RT-PCRanalysis of spexin andGAPDHexpression inhumanmuscle and connective
tissues. (B) Quantitative PCR results of relative mRNA expression level in human muscle and connective tissues. The results were normalized using GAPDH as a reference
gene. Relative spexin expression is calculated relative to the expression of spexin in skeletal muscle. (C) Immunohistochemical staining with spexin antiserum in human
muscle and connective tissues. Bars: Skeletal = 25m; Skeletal muscle and Connective tissue, Smooth muscle(uterus), Smooth muscle(bladder) = 100m.
in T2DM, which may represent an adaptation to the rise of glucose
and lipid associated with T2DM. However, the exact physiologi-
cal and/or pathophysiological role of spexin in endocrine diseases,
particularly the effect of spexin on glucose and lipid metabolism,
remains to be elucidated.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgments
Grateful acknowledgement is made to Dr. Rui Liu who gave us
considerable help bymeans of experimental design. We also thank
DavidDuchenne, JennyXu, EddieK. KwongandGeYan for linguistic
advice and editorial assistance. This work was supported by the
National Natural Science Foundation of China (Grant No. 81370904
and Grant No. 81100616).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.peptides.2015.
07.018
References
[1] O. Mirabeau, E. Perlas, C. Severini, E. Audero, O. Gascuel, et al., Identiﬁcation of
novel peptide hormones in the human proteome by hidden Markov model
screening, Genome Res. (2007) 320–327.
[2] K. Sonmez, N.T. Zaveri, I.A. Kerman, S. Burke, C.R. Neal, et al., Evolutionary
sequence modeling for discovery of peptide hormones, PLoS Comput. Biol. 5
(2009) e1000258.
[3] A. Porzionato, M. Rucinski, V. Macchi, C. Stecco, L.K. Malendowicz, et al.,
Spexin expression in normal rat tissues, J. Histochem. Cytochem. 58 (2010)
825–837.
[4] M. Rucinski, A. Porzionato, A. Ziolkowska, M. Szyszka, V. Macchi, et al.,
Expression of the spexin gene in the rat adrenal gland and evidences
suggesting that spexin inhibits adrenocortical cell proliferation, Peptides 31
(2010) 676–682.
[5] L. Toll, T.V. Khroyan, K. Sonmez, A. Ozawa, I. Lindberg, et al., Peptides derived
from the prohormone proNPQ/spexin are potent central modulators of
cardiovascular and renal function and nociception, FASEB J. 26 (2012)
947–954.
[6] Y. Liu, S. Li, X. Qi, W. Zhou, X. Liu, et al., A novel neuropeptide in suppressing
luteinizing hormone release in goldﬁsh, Carassius auratus, Mol. Cell.
Endocrinol. 374 (2013) 65–72.
[7] M.K. Wong, K.H. Sze, T. Chen, C.K. Cho, H.C. Law, et al., Goldﬁsh spexin:
solution structure and novel function as a satiety factor in feeding control,
Am. J. Physiol. Endocrinol. Metab. 305 (2013) E348–E366.
[8] J.L. Walewski, F. Ge, Lobdell Ht, N. Levin, G.J. Schwartz, et al., Spexin is a novel
human peptide that reduces adipocyte uptake of long chain fatty acids and
causes weight loss in rodents with diet-induced obesity, Obesity (Silver
Spring) 22 (2014) 1643–1652.
[9] Expert Committee on the Diagnosis, Classiﬁcation of Diabetes Mellitus, Report
of the expert committee on the diagnosis and classiﬁcation of diabetes
mellitus. Diabetes Care, 26, Suppl. 1, 2003, S5–20.
[10] A. Ziolkowska, M. Rucinski, C. Tortorella, M. Tyczewska, G.G. Nussdorfer, et al.,
Cultured rat calvarial osteoblast-like cells are provided with orexin type 1
receptors, Int. J. Mol. Med. 20 (2007) 779–782.
[11] C. Tortorella, C. Macchi, R. Spinazzi, L.K. Malendowicz, M. Trejter, et al.,
Ghrelin, an endogenous ligand for the growth hormone-secretagogue
receptor, is expressed in the human adrenal cortex, Int. J. Mol. Med. 12 (2003)
213–217.
[12] M. Rucinski, A. Ziolkowska, M. Szyszka, L.K. Malendowicz, Cerebellin and
des-cerebellin exert ACTH-like effects on corticosterone secretion and the
intracellular signaling pathway gene expression in cultured rat adrenocortical
cells–DNA microarray and QPCR studies, Int. J. Mol. Med. 23 (2009) 539–546.
[13] M. Nadimi, F.O. Stefani, M. Hijri, The mitochondrial genome of the
glomeromycete Rhizophagus sp. DAOM 213,198 reveals an unusual
organization consisting of two circular chromosomes, Genome Biol. Evol. 7
(2014) 96–105.
L. Gu et al. / Peptides 71 (2015) 232–239 239
[14] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods 25
(2001) 402–408.
[15] A. Porzionato, V. Macchi, L. Barzon, G. Masi, M. Iacobone, et al.,
Immunohistochemical assessment of paraﬁbromin in mouse and human
tissues, J. Anat. 209 (2006) 817–827.
[16] M.H. Hanigan, H.F. Frierson Jr., Immunohistochemical detection of
gamma-glutamyl transpeptidase in normal human tissue, J. Histochem.
Cytochem. 44 (1996) 1101–1108.
[17] A. Porzionato, M. Rucinski, V. Macchi, C. Stecco, G. Sarasin, et al., Spexin is
expressed in the carotid body and is upregulated by postnatal hyperoxia
exposure, Adv. Exp. Med. Biol. 758 (2012) 207–213.
[18] D.K. Kim, S. Yun, G.H. Son, J.I. Hwang, C.R. Park, et al., Coevolution of the
Spexin/Galanin/Kisspeptin Family: Spexin Activates Galanin Receptor Type II
and III, Endocrinology 155 (2014) 1864–1873.
[19] I. Legakis, T. Mantzouridis, T. Mountokalakis, Positive correlation of galanin
with glucose in type 2 diabetes, Diabetes Care 28 (2005) 759–760.
[20] P. Fang, M. Yu, M. Shi, Z. Zhang, Y. Sui, et al., Galanin peptide family as a
modulating target for contribution to metabolic syndrome, Gen. Comp.
Endocrinol. 179 (2012) 115–120.
[21] P. Fang, M. Yu, L. Guo, P. Bo, Z. Zhang, et al., Galanin and its receptors: a novel
strategy for appetite control and obesity therapy, Peptides 36 (2012) 331–339.
[22] P. Fang, W. Min, Y. Sun, L. Guo, M. Shi, et al., The potential antidepressant and
antidiabetic effects of galanin system, Pharmacol. Biochem. Behav. 120C
(2014) 82–87.
[23] L. Guo, M. Shi, L. Zhang, G. Li, L. Zhang, et al., Galanin antagonist increases
insulin resistance by reducing glucose transporter 4 effect in adipocytes of
rats, Gen. Comp. Endocrinol. 173 (2011) 159–163.
